Sponsor: Aravive, Inc.
Sponsor Study ID: AVB500-OC-004
Study Title: A Phase 3, Randomized, Double Blind, Adaptive, Placebo/Paclitaxel Controlled Study of AVB S6 500 in Combination With Paclitaxel in Patients With Platinum Resistant Recurrent Ovarian Cancer
CTO #: 103401
NCT Number: NCT04729608
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Ovary
Study Objectives: This is a Phase 3 study of AVB-S6-500 in combination with paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer. This is a randomized, double-blind, placebo-controlled study to compare efficacy and tolerability of AVB-S6-500 in combination with Pac versus placebo plus Pac.